How does cost-sharing affect drug purchases insurance regimes in the private market for prescription drugs

Journal of Economics and Management Strategy

Volumn 19, Issue 3, 2010, Pages 545-574

  Dor, Avi ^a   Encinosa, William ^b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955348895     PISSN: 10586407     EISSN: 15309134     Source Type: Journal    
DOI: 10.1111/j.1530-9134.2010.00261.x     Document Type: Article

References (45)

1. Becker S, Ichino A. Estimation of Average Treatment Effects Based on Propensity Scores. The Stata Journal 2002, 2(4):358-377.
2. Bymark L, Waite K. Prescription Drug Use and Expenditures in California: Key Trends and Drivers 2001, Oakland, CA, California HealthCare Foundation
3. Chernew M, Encinosa W, Hirth R. Optimal Health Insurance: The Case of Multiple Treatment Options. Journal of Health Economics 2000, 19:585-609.
4. Cohen FJ, Neslusan CA, Conklin JE, Song X. Recent Hyperglycemic Trends for U.S. Privately Insured Patients With Type 2 Diabetes. Diabetes Care 2003, 26:1847-1851.
5. Crown WH, Brendt ER, Baser O. Benefit Plan Design and Prescription Drug Utilization Among Asthmatics: Do Patient Copayments Matter. 2003, NBER Working Paper No. 10062, Cambridge, MA
6. Dehejia R, Wahba S. Propensity Score-Matching Methods for Nonexperimental Causal Studies. Review of Economics and Statistics 2002, 84(1):151-161.
7. Dehejia R, Wahba S. Practical Propensity Score Matching: A Reply to Smith and Todd. Journal of Econometrics 2005, 125(1-2):355-364.
8. Dezii CM. Medication Noncompliance: What is the Problem. Managed Care 2000, 9(9):12-17.
9. Dor A. Optimal Price Rules, Administered Prices and Suboptimal Prevention: Evidence from a Medicare Program. Journal of Regulatory Economics 2004, 25(1):81-104.
10. Elixhauser A, Steiner C, Harris D, Coffey R. Comorbidity Measures for Use With Administrative Data. Medical Care 1988, 36(1):8-27.
11. Ellis JJ, Erickson SR, Stevenson JG, Bemstein SJ, Stiles RA, Fendrick MA. Suboptimal Statin Adherence and Discontinuation in Primary and Secondary Prevention Populations: Should We Target Patients with the Most to Gain. Journal of General Internal Medicine 2004, 19(6):638-645.
12. Ellison SF, Cockburn I, Griliches Z, Hausman J. Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins. RAND Journal of Economics 1997, 28(3):426-446.
13. Encinosa W. Pharmacy Benefit Design Options Available to Employers. Expert Review of Pharmacoeconomics and Outcomes Research 2002, 2(4):389-396.
14. Frank R. Prescription-Drug Prices. New England Journal of Medicine 2004, 351(14):1375-1377.
15. Fuhrmans V. A Radical Prescription. Wall Street Journal 2004, R3-R4. May 10
16. Gilberg K, Laouri M, Wade S, Isonaka S. Analysis of Medication Use Patterns: Apparent Overuse of Antibiotics and Underuse of Prescription Drugs for Asthma, Depression, and CHF. Journal of Managed Care Pharmacy 2003, 9(3):232-237.
17. Glazer J, McGuire TG. Multiple Payers, Commonality and Free-Riding in Health Care: Medicare and Private Payers. Journal of Health Economics 2002, 21(6):1049-1069.
18. Goldman D. Pharmacy Benefits and the Use of Drugs by the Chronically Ill. Journal of the American Medical Association 2004, 291(19):2344-2350.
19. Survey Findings: Health Care Expenditures: Future Strategy and Direction 2002 2002, Hewitt Associates, Lincolnshire, IL, Hewitt Associates
20. Hsu J. Unintended Consequences of Caps on Medicare Drug Benefits. New England Journal of Medicine 2006, 354(22):2349-2359.
21. Huskamp H. The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and Spending. New England Journal of Medicine 2003, 349(23):2224-2232.
22. Hughes DA. Accounting for Non-Compliance in Pharmacoeconomic Evaluations. Pharmacoeconomics 2001, 19(12):1185-1197.
23. Inzucchi S. Oral Antihyperglycemic Therapy for Type 2 Diabetes. Journal of the American Medical Association 2002, 287(3):360-372.
24. Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer Drug Benefit Plans and Spending On Prescription Drugs. Journal of the American Medical Association 2002, 288(4):1733-1739.
25. Karter AJ. Out-of-Pocket Costs and Diabetes Prevention Services. Diabetes Care 2003, 26(8):2294-2299.
26. Leatherman S, McCarthy D. Quality of Health Care in the United States: A Chartbook 2002, New York, The Commonwealth Fund
27. Leuven E, Sianesi B. PSMATCH2: Stata Module to Perform Full Mahalanobis and Propensity Score Matching, Common Support Graphing, and Covariate Imbalance Testing. 2003, http://ideas.repec.org/c/boc/bocode/s432001.html
28. Liang S, Phillips K, Tye S. Does Patient Cost Sharing Matter Its Impact on Recommended versus Controversial Cancer Screening Services. American Journal of Managed Care 2004, 10(2):99-107.
29. McDonald K, Romano P, Geppert J. Measures of Patient Safety Based on Hospital Administrative Data-The Patient Safety Indicators. Technical Review 5 2002, AHRQ Publication No. 02-0038, Rockville, MD, Agency for Healthcare Research and Quality
30. Ma CA, Riordan M. Health Insurance, Moral Hazard, and Managed Care. Journal of Economics and Management Strategy 2002, 11(1):81-107.
31. Manning WG, Newhouse JP, Duan N, Keeler EB, Leibowitz A, Marquis MS. Health Insurance and the Demand for Medical Care: Evidence from a Randomized Experiment. American Economic Review 1987, 77:251-277.
32. Mood A, Graybill F, Boes D. Introduction to the Theory of Statistics 1974, 3rd edition, New York, McGraw-Hill
33. Agency for Healthcare Research and Quality. 2003, National Healthcare Quality Report, U.S. Department of Health and Human Services, Rockville, MD
34. Agency for Healthcare Research and Quality. 2008, National Healthcare Quality Report, U.S. Department of Health and Human Services, Rockville, MD
35. Newhouse JP. Free for All Lessons from the RAND Health Insurance Experiment 1993, and, the Insurance Experiment Group, Cambridge, Harvard University Press
36. Pauly MV. Overinsurance and the Public Provision Of Insurance: The Role Of Moral Hazard And Adverse Selection. Quarterly Journal of Economics 1974, 88(1):44-62.
37. Ridley D. Payments, Promotion, and the Purple Pill, Fuqua School of Business. 2004, Duke University, Working Paper
38. Rizzo JA, Simons WR. Variations in Compliance Among Hypertensive Patients By Drug Class. Clinical Therapeutics 1997, 19(6):1446-1457.
39. Rosenbaum PR, Rubin DB. Constructing a Control Group Using Multivariate Matched Sampling Methods That Incorporate the Propensity Score. The American Statistician 1985, 39(1):33-38.
40. Stagnitti MN. Comparing Population Characteristics of Persons Purchasing Prescribed Drugs from Mail Order Pharmacies with Persons Purchasing Prescribed Drugs from Other Outlets, 2005. Statistical Brief 200. February 2008 2008, http://www.meps.ahrq.gov/mepsweb/data_files/publications/st200/stat200.pdf, Agency for Healthcare Research and Quality, Rockville, MD
41. Steiner J, Prochazka A. The Assessment of Refill Compliance Using Pharmacy Records: Methods, Validity, and Applications. Journal of Clinical Epidemiology 1997, 50(1):105-116.
42. Thomas CP, Wallack SS, Lee S, Ritter GA. Impact of Health Plan Design and Management on Retirees' Prescription Drug Use and Spending. Health Affairs 2002, v21:w408-w409.
43. Woellert L. Soon We Will All Be Paying More for Prescription Drugs. Business Week 2002, May 6
44. Yang Z, Guilleskie D, Norton E. Prescription Drugs, Medical Care, and Health Outcomes: A Model of Elderly Health Dynamics. 2004, NBER Working Paper No. 10964, Cambridge, MA
45. Zweifel P. Bonus Options in Health Insurance 1995, London, Kluwer